Litcius/Paper detail

Construction of relapse-related lncRNA-mediated ceRNA networks in Hodgkin lymphoma

Yuexiong Liang, Haifeng Zhu, Jing Chen, Wei Lin, Bing Li, Yusheng Guo

2020Archives of Medical Science23 citationsDOIOpen Access PDF

Abstract

INTRODUCTION: Hodgkin lymphoma (HL) is a type of lymphoma common throughout the western countries. However, the detailed mechanisms and special biomarkers of HL remain to be further investigated. Emerging studies have shown that long non-coding RNAs play a key role in human cancers. MATERIAL AND METHODS: In the present work, we constructed relapse-related lncRNA-mediated ceRNA networks in HL. Additionally, we constructed co-expression networks for these relapse-related lncRNAs. We also constructed a relapse-related lncRNA-miRNA-mRNA network to study the potential mechanism of these lncRNAs. Furthermore, gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis were performed to explore functions of DEGs in Hodgkin lymphoma. RESULTS: A total of 18 lncRNAs were found to be dysregulated between early relapse and late relapse HL. Six lncRNAs (PCBP1-AS1, HCG18, GAS5, PSMD6-AS2, PRKCQ-AS1, SNHG6), 116 mRNAs and 121 miRNAs were included in the ceRNA network. Bioinformatics analyses revealed that these lncRNAs were significantly involved in regulating immune system processes, responses to chemical stimuli and responses to stress. Among them, HCG18 and PCBP1-AS1 were identified as key lncRNAs in HL relapse. CONCLUSIONS: Our results for the first time constructed the key relapse-related lncRNA-mediated ceRNA networks in Hodgkin lymphoma progression. We trust that this work will provide a new therapeutic and prognostic target for HL.

Topics & Concepts

Competing endogenous RNAKEGGmicroRNALymphomaMedicineMechanism (biology)Hodgkin lymphomaComputational biologyGeneGene ontologyLong non-coding RNACancer researchBioinformaticsBiologyGene expressionRNAImmunologyGeneticsEpistemologyPhilosophyCancer-related molecular mechanisms researchLymphoma Diagnosis and TreatmentCircular RNAs in diseases